×
About 385 results

ALLMedicine Primary Prevention of Cardiovascular Disease Center

Research & Reviews  169 results

The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A ...
https://doi.org/10.1007/s40266-019-00736-y
Drugs & Aging; Zhou Z, Albarqouni L et. al.

Jan 10th, 2020 - The use of statins in the primary prevention of cardiovascular disease (CVD) is increasing in older adults. Nonetheless, good clinical evidence for the safety and tolerability of statins in this population is limited. We aimed to evaluate the safe...

Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Imp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951082
Journal of the American Heart Association; Fernandez-Jimenez R, Wang TJ et. al.

Dec 11th, 2019 - Background Data are limited on use patterns of low-dose aspirin and its role for primary prevention of cardiovascular disease (CVD) in different racial and ethnic groups. Methods and Results Overall, 65 231 non-Hispanic black and white people aged...

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886850
PloS One; Jiang M, Li P et. al.

Dec 3rd, 2019 - The use of aspirin for primary prevention of cardiovascular disease (CVD) in patients with diabetes mellitus (DM) is associated with lower rates of cardiovascular events but increased risks of bleeding complications. We aimed to examine the cost-e...

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a partic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827248
BMC Medicine; Gelbenegger G, Postula M et. al.

Nov 4th, 2019 - The role of aspirin in primary prevention of cardiovascular disease (CVD) remains unclear. We aimed to investigate the benefit-risk ratio of aspirin for primary prevention of CVD with a particular focus on subgroups. Randomized controlled trials c...

Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit–Harm Analysis
https://annals.org/aim/article-abstract/2751452/personalized-prediction-cardiovascular-benefits-bleeding-harms-from-aspirin-primary-prevention

Sep 16th, 2019 - Background: Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear. Objective: To identify persons without CVD for whom aspirin would probably result in a...

see more →

Guidelines  2 results

Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit–Harm Analysis
https://annals.org/aim/article-abstract/2751452/personalized-prediction-cardiovascular-benefits-bleeding-harms-from-aspirin-primary-prevention

Sep 16th, 2019 - Background: Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear. Objective: To identify persons without CVD for whom aspirin would probably result in a...

Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabol...
https://doi.org/10.1210/jc.2008-0222
The Journal of Clinical Endocrinology and Metabolism; Rosenzweig JL, Ferrannini E et. al.

Jul 30th, 2008 - The objective was to develop clinical practice guidelines for the primary prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in patients at metabolic risk. Healthcare providers should incorporate into their practice con...

see more →

Clinicaltrials.gov  193 results

The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A ...
https://doi.org/10.1007/s40266-019-00736-y
Drugs & Aging; Zhou Z, Albarqouni L et. al.

Jan 10th, 2020 - The use of statins in the primary prevention of cardiovascular disease (CVD) is increasing in older adults. Nonetheless, good clinical evidence for the safety and tolerability of statins in this population is limited. We aimed to evaluate the safe...

Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease: Use Patterns and Imp...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951082
Journal of the American Heart Association; Fernandez-Jimenez R, Wang TJ et. al.

Dec 11th, 2019 - Background Data are limited on use patterns of low-dose aspirin and its role for primary prevention of cardiovascular disease (CVD) in different racial and ethnic groups. Methods and Results Overall, 65 231 non-Hispanic black and white people aged...

Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886850
PloS One; Jiang M, Li P et. al.

Dec 3rd, 2019 - The use of aspirin for primary prevention of cardiovascular disease (CVD) in patients with diabetes mellitus (DM) is associated with lower rates of cardiovascular events but increased risks of bleeding complications. We aimed to examine the cost-e...

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a partic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827248
BMC Medicine; Gelbenegger G, Postula M et. al.

Nov 4th, 2019 - The role of aspirin in primary prevention of cardiovascular disease (CVD) remains unclear. We aimed to investigate the benefit-risk ratio of aspirin for primary prevention of CVD with a particular focus on subgroups. Randomized controlled trials c...

Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit–Harm Analysis
https://annals.org/aim/article-abstract/2751452/personalized-prediction-cardiovascular-benefits-bleeding-harms-from-aspirin-primary-prevention

Sep 16th, 2019 - Background: Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear. Objective: To identify persons without CVD for whom aspirin would probably result in a...

see more →

News  21 results

Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit–Harm Analysis
https://annals.org/aim/article-abstract/2751452/personalized-prediction-cardiovascular-benefits-bleeding-harms-from-aspirin-primary-prevention

Sep 16th, 2019 - Background: Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear. Objective: To identify persons without CVD for whom aspirin would probably result in a...

"It's Not You, It's Me" - Is it Time to Break Up With Aspirin?
https://www.medscape.com/viewarticle/916006

Jul 24th, 2019 - This article is republished with permission from the ACC. For more, see www.ACC.org. "It's not you, it's me" is the classic relationship breakup adage used to try to soften the blow of the breakup and indicate that it's not the fault of the person...

CVD Primary Prevention Guideline Puts Patients Center Stage
https://www.medscape.com/viewarticle/911224

Apr 10th, 2019 - This transcript has been edited for clarity. Salim S. Virani, MD, PhD, FACC: Hello. I'm Salim Virani from Baylor College of Medicine. I'm joined today by my two colleagues Dr Erin Michos, from Johns Hopkins School of Medicine, and Dr Donna Arnett,...

Cardiovascular Disease Primary Prevention Clinical Practice Guidelines (ACC/AHA 2019)
https://www.medscape.com/viewarticle/910890

Mar 25th, 2019 - The American College of Cardiology (ACC) and the American Heart Association (AHA) published recommendations on the primary prevention of cardiovascular disease (CVD) in March 2019.[1,2] Ten key messages and a few recommendations from the guideline...

Most Patients Don't Meet CV Primary Prevention Treatment Targets: EUROASPIRE V
https://www.medscape.com/viewarticle/906868

Dec 19th, 2018 - DUBAI, United Arab Emirates — Fewer than half of patients receiving therapy for hypertension, dyslipidemia, or diabetes in primary care practices, mainly in Europe, meet guideline treatment targets for primary prevention of cardiovascular disease ...

see more →